{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:40:51Z","timestamp":1783989651338,"version":"3.55.0"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"11","funder":[{"name":"Cardiovascular Research Foundation, New York, NY, USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Given conflicting data on temporal variability in pharmacodynamic platelet responses to clopidogrel, we investigated platelet reactivity on clopidogrel and aspirin for up to six months after elective percutaneous coronary intervention (PCI) with drug-eluting stents. Platelet reactivity was determined in 102 patients before loading with clopidogrel and aspirin, and on maintenance therapy after PCI on day 1, at one month and six months by VerifyNow\u2122 P2Y12 and Aspirin assays and by residual platelet aggregation (RPA) on light transmission aggregometry using adenosine diphosphate and arachidonic acid. By VerifyNow testing, median (interquartile range) P2Y12 reaction units (PRU) on clopidogrel were 166 (90\u2013234), 195 (124\u2013257), and 198 (141\u2013252) on day 1, one month and six months after PCI, respectively (p=0.005 day 1 to 1 month, and p=0.86 1 month to 6 months). Using a cut-off of &gt; 208 PRU, 35% of patients had high platelet reactivity (HPR) to clopidogrel on day 1, 43% at one month, and 46% at six months after PCI. Between day 1 and six months after PCI, 38.2% of patients changed clopidogrel responder status at least once. Other cut-offs and RPA yielded similar results. Platelet inhibition by aspirin was consistent over time with only five patients being characterised as having HPR. Considerable variation in individual on-clopidogrel platelet reactivity was present during both the subacute and the late phases of maintenance therapy after elective PCI. Hence, the utility of contemporary platelet function testing to guide antiplatelet therapy may be limited.<\/jats:p>","DOI":"10.1160\/th15-03-0257","type":"journal-article","created":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T10:32:53Z","timestamp":1440498773000},"page":"1020-1027","source":"Crossref","is-referenced-by-count":15,"title":["Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation"],"prefix":"10.1160","volume":"114","clinical-trial-number":[{"clinical-trial-number":"nct00638794","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christian","family":"Stratz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leggewie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willibald","family":"Hochholzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Valina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay J.","family":"Kirtane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Josef","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trenk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"N\u00fchrenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"10.1160\/TH15-03-0257-1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.07.041"},{"key":"10.1160\/TH15-03-0257-2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.12.056"},{"key":"10.1160\/TH15-03-0257-3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.11.030"},{"key":"10.1160\/TH15-03-0257-4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp402"},{"key":"10.1160\/TH15-03-0257-5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.181"},{"key":"10.1160\/TH15-03-0257-6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.08.057"},{"key":"10.1160\/TH15-03-0257-7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029165"},{"key":"10.1160\/TH15-03-0257-8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61170-8"},{"key":"10.1160\/TH15-03-0257-9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.290"},{"key":"10.1160\/TH15-03-0257-10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209979"},{"key":"10.1160\/TH15-03-0257-11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.026"},{"key":"10.1160\/TH15-03-0257-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.12.047"},{"key":"10.1160\/TH15-03-0257-13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.051"},{"key":"10.1160\/TH15-03-0257-14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000160869.75810.98"},{"key":"10.1160\/TH15-03-0257-15","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2006.28.5.990205"},{"key":"10.1160\/TH15-03-0257-16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1332"},{"key":"10.1160\/TH15-03-0257-17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.12.034"},{"key":"10.1160\/TH15-03-0257-18","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)03014-0"},{"key":"10.1160\/TH15-03-0257-19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.08.047"},{"key":"10.1160\/TH15-03-0257-20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.03.029"},{"key":"10.1160\/TH15-03-0257-21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072771.11429.83"},{"key":"10.1160\/TH15-03-0257-22","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.100891"},{"key":"10.1160\/TH15-03-0257-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2013.03.006"},{"key":"10.1160\/TH15-03-0257-24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1703"},{"key":"10.1160\/TH15-03-0257-25","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2013.827781"},{"key":"10.1160\/TH15-03-0257-26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.06.065"},{"key":"10.1160\/TH15-03-0257-27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.06.002"},{"key":"10.1160\/TH15-03-0257-28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.110.960997"},{"key":"10.1160\/TH15-03-0257-29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH15-03-0257-30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61273-1"},{"key":"10.1160\/TH15-03-0257-31","doi-asserted-by":"crossref","unstructured":"Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328. Saw J, Madsen EH, Chan S, et al. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008; 52: 1826-1833. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 2560-2564. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc 2011; 305: 1097-1105. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965. Saw J, Madsen EH, Chan S, et al. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008; 52: 1826-1833","DOI":"10.1016\/j.jacc.2008.08.047"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH15-03-0257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T16:34:06Z","timestamp":1567096446000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH15-03-0257"}},"subtitle":["An ADAPT-DES substudy"],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,24]]},"published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1160\/th15-03-0257","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}